Kala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call

Rhea-AI Summary

Kala Pharmaceuticals (NASDAQ:KALA) announced it will report its first quarter 2022 financial results on May 16, 2022. A conference call and live audio webcast will follow at 8:00 a.m. ET for discussion of the results and a business update. The public can access the live webcast via the Kala website. The company focuses on innovative eye disease therapies, utilizing its AMPPLIFY® drug delivery technology for products like EYSUVIS® and INVELTYS®. Kala is also advancing its pipeline, including KPI-012 for persistent corneal epithelial defects and new chemical entity programs.

Positive

• Preparation to report Q1 2022 financial results indicates transparency with investors.
• Utilization of AMPPLIFY® technology shows commitment to innovation in ocular therapies.

Negative

• None.

ARLINGTON, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report first quarter 2022 financial results on Monday, May 16, 2022. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.

The dial-in numbers to access this conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 6384677. To access a live webcast and subsequent archived recording of the call, please visit “Events” in the “Investors” section on the Kala website at http://kalarx.com/.

About Kala Pharmaceuticals, Inc.

Kala is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY^® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS^® (loteprednol etabonate ophthalmic suspension) 0.25% and INVELTYS^® (loteprednol etabonate ophthalmic suspension) 1%. The Company also has a pipeline of development programs including a clinical-stage secretome product candidate, KPI-012, initially targeting persistent corneal epithelial defects (PCED) and multiple proprietary new chemical entity (NCE) preclinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases. For more information on Kala, please visit www.kalarx.com.

Investor Contacts:

Jill Steier
jill.steier@kalarx.com
781-996-5252

Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200

 

FAQ

When will Kala Pharmaceuticals report its first quarter 2022 financial results?

Kala Pharmaceuticals will report its first quarter 2022 financial results on May 16, 2022.

What time is the conference call for Kala Pharmaceuticals' financial results?

The conference call will take place at 8:00 a.m. ET on May 16, 2022.

How can I access the conference call for Kala Pharmaceuticals?

To access the conference call, dial 866-300-4091 domestically or 703-736-7433 internationally using conference ID 6384677.

What is the focus of Kala Pharmaceuticals?

Kala Pharmaceuticals focuses on innovative therapies for diseases of the eye, including products like EYSUVIS® and INVELTYS®.

What is the significance of the KPI-012 program for Kala Pharmaceuticals?

KPI-012 targets persistent corneal epithelial defects and represents Kala's commitment to addressing unmet medical needs.